The effect of physical activity on fatigue among survivors of colorectal cancer: a systematic review and meta-analysis.

PURPOSE: Favorable health outcomes among cancer survivors are increasingly being attributed to lifestyle factors like physical activity, which is now promoted in clinical guidelines. However, the available evidence indicates that physical activity may also reduce fatigue in this patient group. In this systematic review, we aimed to examine whether physical activity could reduce fatigue among survivors of colorectal cancer. METHODS: The databases of Medline, CINAHL, and PsycINFO were systematically searched, using combinations of MeSH and free-text terms for colorectal cancer, physical activity, and fatigue. Randomized controlled trials and cohort studies with longitudinal data collection were included. We performed a random-effect meta-analysis. RESULTS: Seven studies were included, five were randomized controlled trials, and two were cohort studies. A meta-analysis of the randomized controlled trials, which comprised 630 survivors in total, failed to show that physical activity had a significant effect on fatigue (standardized mean difference = 0.21 (- 0.07 to 0.49)); however, reduced levels of fatigue were observed in all studies. The results for the cohort studies were inconclusive: one showed that increasing levels of physical activity were significantly associated with decreasing levels of fatigue; the other showed that decreasing levels of fatigue were not associated with increasing levels of physical activity. CONCLUSIONS: Based on the data reviewed, we cannot draw definitive conclusions about the effects of physical activity on fatigue. None of the included studies were performed among fatigued survivors of colorectal cancer. More research is needed in this population, ensuring that the trials are appropriately powered to find differences in fatigue.

An inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine affords clinical protection against BVDV type 2.

This study was designed to answer to two distinct questions. Firstly, is it possible to reproduce clinical signs of acute bovine virus diarrhoea virus (BVDV) type 2 infection including signs of haemorrhagic disease under experimental conditions in cattle at 20 weeks of age? Secondly, what is the extent of the protection afforded by vaccination with an inactivated BVDV type 1 vaccine against BVDV type 2 infection? Calves were vaccinated at 12 and 16 weeks of age with a commercially available inactivated BVDV type 1 vaccine (Bovilis BVD). At 20 weeks they were challenge infected with BVDV type 2 virus together with unvaccinated control calves. The unvaccinated animals developed typical signs of respiratory disease, diarrhoea with erosions and haemorrhages along the whole length gastro-intestinal tract, and depletion of lymphocytes in lymphatic organs. These signs were either absent or markedly less severe in the vaccinated animals. The beneficial effects of vaccination were most striking in the haematological parameters thrombocytopenia and leukopenia. It can be concluded that vaccination with Bovilis BVD affords cross-protection against clinical effects of a challenge-infection with heterologous type 2 BVDV.